within Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XA53_TositumomabIodine131iTositumomab;

model TositumomabIodine131iTositumomab
  extends Pharmacolibrary.Drugs.ATC.V.V10XA53;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>V10XA53</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tositumomab/iodine (131I) tositumomab is a radiolabeled monoclonal antibody formerly used for the treatment of rituximab-refractory, CD20-positive, follicular non-Hodgkin's lymphoma. It combines the murine anti-CD20 IgG2a monoclonal antibody (tositumomab) with radioactive iodine-131 to target malignant B lymphocytes. The drug has been withdrawn from the market and is no longer approved for use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with relapsed or refractory non-Hodgkin's lymphoma; typical values in adults from various clinical reports.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end TositumomabIodine131iTositumomab;
